Rapid Test Covid-19

Anti-SARS-CoV-2 Rapid Test, COVID-19 1. Easier: No special equipment needed, Intuitive visual interpretation. 2. Rapid: Quick sampling by fingertip blood, Results in 10-15min. 3. Accurate: Results with IgG and IgM respectively. 4. Application: as screening tool for potential suspect patients in large numbers. Testing kit is FDA Emergency Use Authorization (EUA) Approved Testing kit is CE MARKED-IVD * Instruction for Use * Interpretation Guide * SARS-CoV-2 immunoassays * Accuracy of the Anti-SARS-CoV-2 Rapid Test Kit * Anti-SARS Rapid Test Brochure * COVID-19 Catalog * EUA Approval Letter * Fact Sheet for Healthcare Providers * FDA Letter * Fact Sheet for Recipients * FAQ * CE IVD Notification Certificate Antibody Performance Measure Estimate of Performance 95% Confidence Interval IgM Sensitivity (PPA) 95.7% (289/302) (92.8%; 97.5%) IgM Specificity (NPA) 99.7% (311/312) (98.2%; 99.9%) IgG Sensitivity (PPA) 99.0% (299/302) (97.1%; 99.7%) IgG Specificity (NPA) 99.4% (310/312) (97.7%; 99.8%) Combined Sensitivity (PPA) 99.0% (299/302) (97.1%; 99.7%) Combined Specificity (NPA) 99% (309/312) (97.2%; 99.7%) Combined PPV at prevalence = 5% 84.4% (64.6%; 94.6%) Combined NPV at prevalence = 5% 99.9% (99.8%; 100%) Testing kit is FDA Emergency Use Authorization (EUA) Approved Testing kit is CE MARKED-IVD * Instruction for Use * Interpretation Guide * SARS-CoV-2 immunoassays * Accuracy of the Anti-SARS-CoV-2 Rapid Test Kit * Anti-SARS Rapid Test Brochure * COVID-19 Catalog * EUA Approval Letter * Fact Sheet for Healthcare Providers * FDA Letter * Fact Sheet for Recipients * FAQ * CE IVD Notification Certificate

380 000 pcs single package SELF-TEST 1pcs KIT Goldsite CE1434 LAIENTEST NASAL Price start from 1.79 IFU inside EN / DE / PL BOX PL / EN / DE Optional PDF IFU FR / IT / ES / DA Our warehouse in Poland! We are authorized distributor

Covi-G (powered by Cipla) Rapid Test kit combines quality, efficacy and convenience - offering precise results in 10-15 mins Features & Benefits Covid IgM-IgG Serologic Rapid Test for COVID-19 is used to qualitatively detect IgG and IgM antibodies against SARS-CoV-2 in whole blood in vitro Precise and effective - Tests for both IgM and IgG antibodies - Sensitivity and specificity comparable to highest available offerings Sensitivity: IgG 92%, IgM 82%; Specificity IgG 97%, IgM 94% - ->92% total accuracy: IgG 96,5% - IgM: 92,8% - High reproducibility (consistent results across the same patient) - High quality, reliable & convenient - Single-prick blood test - 10-15 minutes per test - Intuitive visual interpretation - No specialized training or equipment needed - Portable hence highly scalable - Storage at room temperature (2-30 C) - Conformance to CE (Europe) and ISO manufacturing The Covi-G platform for Rapid Antibody tests has a set of unique and unparalleled offerings SUSTAINABLE QUALITY Validated Declaration of CE conformity - Launched in Feb 2020, among the earliest technologies/ kits to declare CE-compliance, and continuing strong compared to competitors - Under process for receiving USDA E authorization Among only 3 integrated vendors of Rapid tests Developed and manufactured in Europe (Belgium) - One of the very lew players manufacturing in Europe, with zero complaints also certified locations ACCEPTABILITY ACROSS MARKETS Demonstrated capabilities in local countries validation - Independent local studies conducted in Belgium and France, validating the sensitivity and specificity of the product Participated in published research - Covl-G kit compared lavorably with 7 lgFL IgM rapid antibody tests and IgG ELISA in a comparative study published by Elsevier Science Direct, verifying sensitivity of the kit PROVEN COMMERCIAL EXPERIENCE Sold in 25+ countries already - Including Europe, US, Canada, Africa and multiple developed and emerging markets - Under participation in govt tenders Robust manufacturing capability and capacity - ISO-certified manufacturing site - Ability to cater to high manufacturing volumes from Belgium, to ensure adequale QA and commercial viability AFFORDABLE AND SCALABLE Viable to scale up at Institutions and Retail level - Economical cost per-unit established over many months of process improvement and local manufacturing - Can cater to insured as well as out-of pocket populations Continuous improvement through R&D - Multiple rounds of performance testing complete, further testing in 5 reputed hospitals underway in Belgium, France, USA and Canada - Other platforms including Rapid antigen testing also being developed The price is per unit, the minimum is 25000 units

Coronavirus Ag Rapid Test Cassette (Swab) have been placed on the European Market, based on the following performance characteristics (which are also included in the IFU included in each test kit) Coronavirus Ag Rapid Test Cassette (Swab) Method Coronavirus Ag Rapid Test Cassette Total Results Relative Sensitivity: 86.7% Relative Specificity: 100% Accuracy: 96.3% Coronavirus Ag Rapid Test Cassette (Swab) The CE mark has been applied as the products fit the definition of an in vitro diagnostic medical device as defined in the IVD Directive and are classified as a general IVD products as they are not included in List A or List B, and they are not intended to be used by lay users. Please note that this